Cargando…
Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways
In view of an efficient use of the Italian National Health Service-funded healthcare resources, a novel data-processing strategy combining information from multiple sources was developed in a regional cancer network of northern Italy. The goal was to calculate the annual overall cost of care pathway...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369964/ https://www.ncbi.nlm.nih.gov/pubmed/32630745 http://dx.doi.org/10.3390/ijerph17134765 |
_version_ | 1783560890850738176 |
---|---|
author | Altini, Mattia Solinas, Laura Bucchi, Lauro Gentili, Nicola Gallegati, Davide Balzi, William Falcini, Fabio Massa, Ilaria |
author_facet | Altini, Mattia Solinas, Laura Bucchi, Lauro Gentili, Nicola Gallegati, Davide Balzi, William Falcini, Fabio Massa, Ilaria |
author_sort | Altini, Mattia |
collection | PubMed |
description | In view of an efficient use of the Italian National Health Service-funded healthcare resources, a novel data-processing strategy combining information from multiple sources was developed in a regional cancer network of northern Italy. The goal was to calculate the annual overall cost of care pathways of six disease groups in 10,486 patients. The evaluation was conceived as a population-based cost description from the perspective of the Italian National Health Service. Costs occurred during a defined time period for a cross-section of patients at varying stages of their disease were measured. The total cancer care cost was €81,170,121 (11.1% of total local health expenditure), with a cost per patient of €7741.17 and a cost per capita of €204.62. Surgical, inpatient and day-hospital medical admissions, radiotherapy, drugs, outpatient care, emergency admissions, and home and hospice care accounted for 21.2%, 24.1%, 6.2%, 28.2%, 14.0%, 0.9%, and 5.4% of the total cost, respectively. The highest cost items included drugs (cost per capita, €22.95; 11.2% of total cost) and medical admissions (€14.51; 7.1%) for blood cancer, and surgical (€14.56; 7.1%) and medical admissions (€13.60; 6.6%) for gastrointestinal cancer. The information extracted allows multidisciplinary cancer care teams to be more aware of the costs of their clinical decisions. |
format | Online Article Text |
id | pubmed-7369964 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73699642020-07-21 Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways Altini, Mattia Solinas, Laura Bucchi, Lauro Gentili, Nicola Gallegati, Davide Balzi, William Falcini, Fabio Massa, Ilaria Int J Environ Res Public Health Article In view of an efficient use of the Italian National Health Service-funded healthcare resources, a novel data-processing strategy combining information from multiple sources was developed in a regional cancer network of northern Italy. The goal was to calculate the annual overall cost of care pathways of six disease groups in 10,486 patients. The evaluation was conceived as a population-based cost description from the perspective of the Italian National Health Service. Costs occurred during a defined time period for a cross-section of patients at varying stages of their disease were measured. The total cancer care cost was €81,170,121 (11.1% of total local health expenditure), with a cost per patient of €7741.17 and a cost per capita of €204.62. Surgical, inpatient and day-hospital medical admissions, radiotherapy, drugs, outpatient care, emergency admissions, and home and hospice care accounted for 21.2%, 24.1%, 6.2%, 28.2%, 14.0%, 0.9%, and 5.4% of the total cost, respectively. The highest cost items included drugs (cost per capita, €22.95; 11.2% of total cost) and medical admissions (€14.51; 7.1%) for blood cancer, and surgical (€14.56; 7.1%) and medical admissions (€13.60; 6.6%) for gastrointestinal cancer. The information extracted allows multidisciplinary cancer care teams to be more aware of the costs of their clinical decisions. MDPI 2020-07-02 2020-07 /pmc/articles/PMC7369964/ /pubmed/32630745 http://dx.doi.org/10.3390/ijerph17134765 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Altini, Mattia Solinas, Laura Bucchi, Lauro Gentili, Nicola Gallegati, Davide Balzi, William Falcini, Fabio Massa, Ilaria Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways |
title | Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways |
title_full | Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways |
title_fullStr | Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways |
title_full_unstemmed | Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways |
title_short | Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways |
title_sort | assessment of cancer care costs in disease-specific cancer care pathways |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369964/ https://www.ncbi.nlm.nih.gov/pubmed/32630745 http://dx.doi.org/10.3390/ijerph17134765 |
work_keys_str_mv | AT altinimattia assessmentofcancercarecostsindiseasespecificcancercarepathways AT solinaslaura assessmentofcancercarecostsindiseasespecificcancercarepathways AT bucchilauro assessmentofcancercarecostsindiseasespecificcancercarepathways AT gentilinicola assessmentofcancercarecostsindiseasespecificcancercarepathways AT gallegatidavide assessmentofcancercarecostsindiseasespecificcancercarepathways AT balziwilliam assessmentofcancercarecostsindiseasespecificcancercarepathways AT falcinifabio assessmentofcancercarecostsindiseasespecificcancercarepathways AT massailaria assessmentofcancercarecostsindiseasespecificcancercarepathways |